About GlyProVac

GlyProVac is pursuing the development of a glycoprotein based vaccine against Enterotoxigenic Escherichia coli (ETEC).

Company Highlights
Year Founded

2018

icon-altEmployees

10

Location (HQ)

DNK

Since Last Funding

6 months

Monthly Website Visitors

219

icon-altTotal Investment Amt

$500K

Last Funding Round

Grant

icon-altYoY Headcount Growth

24.69%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Biotechnology Research

Biopharma